Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
NCT05321602Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LY03010 in schizophrenia and schizoaffective disorder (4 arms), sponsored by Luye Pharma Group. Primary endpoint: Pharmacokinetic (PK) profiles of paliperidone in LY03010 at 176 days. Started Sep 2021; status: completed.
02
Drugs
LY03010
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT05321602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321602.